Belite Bio, Inc. BLTE 深 滬
等待開盤 08-15 09:30:00 美东时间
69.77
-1.790
-2.50%
華盛通- 最 高70.72
- 今 開70.72
- 成交量 1.68万股
- 最 低 68.78
- 昨 收 71.56
- 總市值 22.71亿
- 52周最高 86.53
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 43.70
- 委 比 75.86%
- 總股本 3254.48万
- 歷史最高 86.53
- 量 比 0.32
- 振 幅 2.71%
- 歷史最低 8.80
- 每 手 1
- 風險率 7.90%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Belite Bio Q2 EPS $(0.50) Misses $(0.40) Estimate
Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.40) by 25.63 percent. This is a 92.31 percent decrease over losses of $(0.26) per share from the
08-11 18:01
Earnings Scheduled For August 11, 2025
Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to rep...
08-11 16:32
Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Belite Bio reported second quarter 2025 financial results with a net loss of $16.3 million and increased R&D and G&A expenses. Key highlights include FDA Breakthrough Therapy Designation for Tinlarebant in Stargardt disease, completion of enrollment in the Phase 3 PHOENIX trial for Geographic Atrophy, and a $15 million registered direct offering. Upcoming milestones include DRAGON trial completion by Q4 2025 and a webcast on August 11, 2025.
08-11 10:00
Belite Bio's Earnings Outlook
Belite Bio (NASDAQ:BLTE) is set to give its latest quarterly earnings report on...
08-08 22:07
Belite Bio announces registered direct offering of $15 million
Belite Bio (NASDAQ:BLTE) on Thursday said it has entered into a securities purchase agreement for the purchase and sale of 230,770 American Depositary Shares and warrants to purchase 230,770 ADSs, at ...
08-07 21:23
Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference
Belite Bio, a clinical-stage drug development company focusing on novel therapeutics for degenerative retinal diseases, announced its participation in the H.C. Wainwright Annual Ophthalmology Virtual Conference on August 13, 2025. The event includes an on-demand corporate presentation at 7:00 am ET and a panel discussion on "Pivotal-Stage Assets for Retinal Disorders" at 11:00 am ET. Webcasts will be available on the company’s investor relations ...
08-06 12:00
Belite Bio to Host Webcast on August 11, 2025, to Discuss Second Quarter 2025 Financial Results
Belite Bio (NASDAQ: BLTE), a clinical-stage drug development company focused on degenerative retinal diseases, will host a webcast on August 11, 2025, at 4:30 p.m. ET to discuss its Q2 2025 financial results and business update. The webcast will be available via the provided link or the company’s Investor Relations website, with a replay accessible for 90 days. Belite Bio is advancing novel therapeutics for conditions like Stargardt disease type ...
08-04 12:00
Belite Bio to Participate in the BTIG Virtual Biotechnology Conference
Belite Bio, a clinical-stage drug development company, announced its executive team will participate in the BTIG Virtual Biotechnology Conference on July 29-30, 2025. The company focuses on novel therapeutics for degenerative retinal diseases, including STGD1 and Geographic Atrophy (GA), with its lead candidate, Tinlarebant, in Phase 3 and Phase 2/3 studies. For more information, visit its website or follow on social media. Media and investor rel...
07-23 12:00
Belite Bio Enrolls 500 Subjects Globally In PHOENIX Trial, Advancing Oral Tinlarebant for Geographic Atrophy In Dry Age-Related Macular Degeneration
500 subjects enrolled across the United States, the United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Australia
07-02 15:27
Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy
Belite Bio has completed enrollment in its PHOENIX trial, a global, 24-month Phase 3 study evaluating the safety and efficacy of Tinlarebant in slowing atrophic lesion growth in patients with geographic atrophy (GA) linked to dry age-related macular degeneration (AMD). The trial enrolled 500 subjects across eight countries, highlighting strong global interest in the potential of this once-daily oral tablet. Tinlarebant aims to address an unmet ne...
07-02 07:00
